Medpace, a global, full-service clinical research organization (CRO), is proud to have once again been recognized with CRO Leadership Awards presented by Life Science Leader and Clinical Leader. This year, Medpace received five awards across all categories, including Capabilities, Compatibility, Expertise, Quality, and Reliability, and across all three groups of respondents (Big Pharma, Small Pharma, and Overall).
“Medpace is honored to be once again recognized across all five CRO Leadership Award categories,” commented Jesse Geiger, President, Medpace. “This recognition is a testament to our talented employees and their commitment to our mission of accelerating clinical development. We strive to operate as an extension of our client’s team – embedding medical, regulatory, and operational expertise into trials to produce streamlined, high-quality results. We take pride in our track record of seamless execution, and we look forward to continuing to exceed sponsor’s expectations in the years to come.”
For the 2023 CRO Leadership Awards, Life Science Leader and Clinical Leader once again teamed up with Industry Standard Research (ISR) to conduct the study and determine the award recipients. 46 contract research organizations were assessed on 20+ performance metrics in ISR’s annual CRO Quality Benchmarking survey to determine the CROs that meet or exceed their customers’ expectations in the categories of Capabilities, Compatibility, Expertise, Quality, and Reliability. Medpace was recognized as having exceeded its customers’ expectations across all five categories.
Survey respondents were selected from biopharmaceutical companies of all sizes, vetted for CRO decision-making authority, and were asked to evaluate only companies they had worked with on an outsourced project in the past 18 months to ensure the data behind the awards are driven by first-hand experience with the CROs being evaluated.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,400 people across 40 countries.